日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction

选择性 ErbB4 激动剂 JK07 治疗射血分数降低的心力衰竭的单次递增剂量研究

Tang, W H Wilson; Steiner, Johannes; Kassi, Mahwash; Wheeler, Matthew T; Spahillari, Aferdita; Sweitzer, Nancy K; Grodin, Justin L; Solomon, Neal; Singhal, Shalabh; McEwen, Amanda M G; Murphy, Samuel L

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Deucravacitinib 是一种口服、选择性、变构酪氨酸激酶 2 抑制剂,用于治疗活动性系统性红斑狼疮 (SLE) 患者:一项 II 期随机试验中患者报告结局的疗效

Mosca, Marta; Arnaud, Laurent; Askanase, Anca; Hobar, Coburn; Becker, Brandon; Singhal, Shalabh; Banerjee, Subhashis; Pomponi, Samantha; Choi, Jiyoon; Strand, Vibeke

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

Deucravacitinib(一种酪氨酸激酶 2 抑制剂)治疗系统性红斑狼疮:一项 II 期随机、双盲、安慰剂对照试验

Morand, Eric; Pike, Marilyn; Merrill, Joan T; van Vollenhoven, Ronald; Werth, Victoria P; Hobar, Coburn; Delev, Nikolay; Shah, Vaishali; Sharkey, Brian; Wegman, Thomas; Catlett, Ian; Banerjee, Subhashis; Singhal, Shalabh

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

选择性TYK2抑制剂deucravacitinib在银屑病关节炎II期试验中的疗效和安全性

Mease, Philip J; Deodhar, Atul A; van der Heijde, Désirée; Behrens, Frank; Kivitz, Alan J; Neal, Jeffrey; Kim, Jonghyeon; Singhal, Shalabh; Nowak, Miroslawa; Banerjee, Subhashis

Use of bicycle exercise echocardiography for unexplained exertional dyspnea.

自行车运动超声心动图在不明原因的运动性呼吸困难中的应用

Singhal Shalabh, Yousuf Mian A, Weintraub Neal L, Shizukuda Yukitaka